ERBB2 and breast carcinoma: Isono et al. described a MGMT protein expression profile in different breast cancer subtypes: In luminal breast cancer 67% were MGMT high expressing (high), 46% in the TNBC cohort and 30% in the HER2 positive cohort, with a p-value of < 0.001 [25].